[go: up one dir, main page]

AR131906A1 - THERAPEUTIC COMPOUNDS - Google Patents

THERAPEUTIC COMPOUNDS

Info

Publication number
AR131906A1
AR131906A1 ARP240100394A ARP240100394A AR131906A1 AR 131906 A1 AR131906 A1 AR 131906A1 AR P240100394 A ARP240100394 A AR P240100394A AR P240100394 A ARP240100394 A AR P240100394A AR 131906 A1 AR131906 A1 AR 131906A1
Authority
AR
Argentina
Prior art keywords
therapeutic compounds
pharmaceutically acceptable
acceptable salt
compound
formula
Prior art date
Application number
ARP240100394A
Other languages
Spanish (es)
Inventor
Paul Matthew Blaney
Michael Beaumont
George Hynd
Oliver Thomas Kern
Original Assignee
C4X Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2302445.8A external-priority patent/GB202302445D0/en
Priority claimed from GBGB2400765.0A external-priority patent/GB202400765D0/en
Application filed by C4X Discovery Ltd filed Critical C4X Discovery Ltd
Publication of AR131906A1 publication Critical patent/AR131906A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un compuesto con la fórmula (1), o una sal aceptable desde un punto de vista farmacéutico de este. Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 25, o una sal aceptable desde un punto de vista farmacéutico de este, y uno o más excipientes aceptables desde un punto de vista farmacéutico.A compound of formula (1), or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising a compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

ARP240100394A 2023-02-21 2024-02-21 THERAPEUTIC COMPOUNDS AR131906A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2302445.8A GB202302445D0 (en) 2023-02-21 2023-02-21 Therapeutic compounds
GBGB2400765.0A GB202400765D0 (en) 2024-01-19 2024-01-19 Therapeutic compounds

Publications (1)

Publication Number Publication Date
AR131906A1 true AR131906A1 (en) 2025-05-14

Family

ID=90361647

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100394A AR131906A1 (en) 2023-02-21 2024-02-21 THERAPEUTIC COMPOUNDS

Country Status (9)

Country Link
EP (1) EP4669637A1 (en)
KR (1) KR20250152075A (en)
CN (1) CN120957974A (en)
AR (1) AR131906A1 (en)
AU (1) AU2024226489A1 (en)
IL (1) IL322849A (en)
MX (1) MX2025009815A (en)
TW (1) TW202448866A (en)
WO (1) WO2024175907A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026018017A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds
WO2026018016A1 (en) * 2024-07-19 2026-01-22 C4X Discovery Limited Therapeutic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773573A4 (en) * 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. HUMAN INTEGRIN ANTAGONISTS (ALPHA4) (BETA7)
RS66976B1 (en) * 2019-10-16 2025-07-31 Morphic Therapeutic Inc INHIBITION OF HUMAN INTEGRIN ALPHA4BETA7

Also Published As

Publication number Publication date
IL322849A (en) 2025-10-01
KR20250152075A (en) 2025-10-22
MX2025009815A (en) 2025-09-02
WO2024175907A1 (en) 2024-08-29
EP4669637A1 (en) 2025-12-31
TW202448866A (en) 2024-12-16
CN120957974A (en) 2025-11-14
AU2024226489A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
AR131906A1 (en) THERAPEUTIC COMPOUNDS
AR132338A1 (en) RAS INHIBITORS
CO2022012975A2 (en) Biaryl derivatives as inhibitors of yap/taz-tead protein-protein interaction
AR134265A1 (en) HETEROCYCLES AND THEIR USES
AR133988A1 (en) RAS-PI3K INHIBITORS AND THEIR USES
AR131639A1 (en) KIF18A INHIBITORS AND THEIR USES
AR128932A1 (en) BCL-XL INHIBITORS
PE20251667A1 (en) Cyclic thiazolyl urea compounds for the treatment of HSV
MX2024011179A (en) Multicyclic compounds
AR129979A1 (en) CYCLIC COMPOUNDS AND METHODS OF USING THEM
AR132764A1 (en) TYK2 INHIBITORS AND THEIR USES
AR125059A1 (en) SELECTIVE DEGRADERS OF THE ESTROGEN RECEPTOR
AR130303A1 (en) PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
AR132166A1 (en) NLRP3 INFLAMMASOME INHIBITORS AND THEIR USES
AR125934A1 (en) MACROCYCLIC COMPOUNDS TO TREAT DISEASES
AR129460A1 (en) INDOLIZINE DERIVATIVES FOR TREATMENT OF TRPM3-MEDIATED DISORDERS
AR124982A1 (en) MACROCYCLES AND THEIR USES
AR129588A1 (en) KRAS INHIBITORS
AR133115A1 (en) KRAS INHIBITORS
AR128868A1 (en) TYK2 INHIBITOR FORMULATIONS AND METHODS FOR PREPARING THEM
AR128780A1 (en) NLRP3 MODULATORS
AR134206A1 (en) DEGRADATORS AND THEIR USES
AR131850A1 (en) LACTAM-SUBSTITUTED IMIDAZOTRIAZINE IL-17A MODULATORS AND THEIR USES
AR126834A1 (en) PSILOCINE PRODRUGS AND DERIVATIVES AND USES OF THESE
AR130282A1 (en) PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIATED DISORDERS